Silence Therapeutics presenting positive siRNA data in Stockholm

Silence Therapeutics announced on Friday that it would be presenting data on its siRNA conjugate technology and lead candidate SLN124, for the treatment of iron overload disorders, at the 23rd Annual European Hematology Association (EHA) Congress, happening in Stockholm.